Efficacy of Small Subcutaneous Glucagon Dose to Treat Hypoglycemia in Adults With Type 1 Diabetes
Status:
Withdrawn
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
In the unfortunate case of severe hypoglycaemia, glucagon is the first-line treatment because
of its potent and rapid action starting as fast as 5 minutes after subcutaneous or
intramuscular injection. Large dose of glucagon such as 1 mg subcutaneous is usually
associated with undesirable side-effects such as nausea, vomiting, bloating and headache.
The overall objective of this research proposal is to assess the efficacy of lower
subcutaneous doses of glucagon (0.1 mg or 0.2 mg) to correct hypoglycaemia compared to the
standard dose (1.0 mg) in adults with type 1 diabetes mellitus (T1D).
It is postulated that much lower dosages of glucagon (0.1 or 0.2 mg) injected subcutaneously
will be just as effective as the current recommended dose of 1.0 mg to correct hypoglycaemia
without the undesirable gastro-intestinal side effects.